Skip to main content

Bristol-Myers Squibb vs Pfizer: Founders, CEOs and History

Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. Pfizer was founded in 1849 by Charles Pfizer, Charles Erhart and is led by Albert Bourla.

Company facts

Bristol-Myers Squibb

Founded
1887
Headquarters
Princeton, New Jersey
Current CEO
Christopher Boerner
Employees
32,500

Pfizer

Founded
1849
Headquarters
New York, New York
Current CEO
Albert Bourla
Employees
75,000

Founders

Bristol-Myers Squibb

  • Edward Robinson Squibb

    Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.

  • William McLaren Bristol

    In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.

  • John Ripley Myers

    Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.

Bristol-Myers Squibb founders in full

Pfizer

  • Charles Pfizer

    Pfizer possesses a historic, immigrant founding story, rooted entirely in the rapid industrial expansion of 19th-century Brooklyn and defined by an effective, intensely meticulous German chemist and his ambitious confectioner cousin.

  • Charles Erhart

    Charles Erhart's role in Pfizer's founding is less celebrated than his cousin's, partly because the company carries Charles Pfizer's name and partly because his commercial contributions were less visible than the scientific achievements that drove the company'…

Pfizer founders in full

CEOs and their tenures

Bristol-Myers Squibb

  1. Charles A. Heimbold Jr.1994–2001

    Chief Executive Officer

    Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.

    Source
  2. Peter R. Dolan2001–2006

    Chief Executive Officer

    Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.

    Source
  3. James M. Cornelius2006–2010

    Chief Executive Officer

    Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.

    Source
  4. Lamberto Andreotti2010–2015

    Chief Executive Officer

    Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.

    Source
  5. Giovanni Caforio2015–2023

    Chief Executive Officer

    Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.

    Source
  6. Chris Boerner2023–present

    Board Chair and Chief Executive Officer

    Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.

    Source
Bristol-Myers Squibb CEO history in full

Pfizer

  1. Ian Read2010–2018

    Chief Executive Officer

    He ruthlessly cut R&D spending and eliminated tens of thousands of jobs, significantly boosting short-term earnings per share despite massive patent cliffs for blockbuster drugs like Lipitor.

    Source
  2. Albert Bourla2019–present

    Chairman and Chief Executive Officer

    A veterinarian by training who joined Pfizer Animal Health in 1993, Bourla became CEO on January 1, 2019 and Chairman in 2020.

    Source
  3. Dave Denton2022–2026

    Chief Financial Officer

    As CFO, he aggressively restructured the balance sheet following the Seagen acquisition, prioritizing debt reduction while defending the dividend.

    Source
  4. Chris Boshoff2025–present

    Chief Scientific Officer and President, Research & Development

    He completely restructured the research and development organization to focus on antibody-drug conjugates (ADCs), aggressively expanding Pfizer's pipeline of cancer therapeutics.

    Source
  5. Cecile Guegan2026–present

    Interim Chief Financial Officer

    She modernized the company's internal auditing and compliance structures, ensuring rapid but safe clinical execution for high-priority vaccine programs.

    Source
Pfizer CEO history in full

Timeline: Bristol-Myers Squibb and Pfizer side by side

  1. 1849Pfizer

    Pfizer Founded

    Charles Pfizer and Charles Erhart founded the company in Brooklyn.

  2. 1858Bristol-Myers Squibb

    Edward Robinson Squibb opens his Brooklyn laboratory

    Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.

  3. 1887Bristol-Myers Squibb

    Bristol and Myers buy the Clinton Pharmaceutical Company

    Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.

  4. 1898Bristol-Myers Squibb

    Bristol, Myers and Company is named

    The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.

  5. 1944Bristol-Myers Squibb

    Penicillin at wartime scale

    Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.

  6. 1944Pfizer

    Penicillin Scale-Up

    Pfizer helped industrialize penicillin production during World War II.

  7. 1989Bristol-Myers Squibb

    Bristol-Myers and Squibb merge

    Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.

  8. 1998Pfizer

    Viagra Approved

    The FDA approved Viagra in 1998.

  9. 2000Pfizer

    Warner-Lambert Deal

    Pfizer acquired Warner-Lambert, adding Lipitor.

  10. 2006Bristol-Myers Squibb

    CEO Peter Dolan removed over the Plavix deal

    After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.

  11. 2009Bristol-Myers Squibb

    Medarex bought and Mead Johnson split off

    BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.

  12. 2009Pfizer

    Wyeth Acquired

    Pfizer bought Wyeth in 2009 for about $68 billion.

  13. 2011Bristol-Myers Squibb

    FDA approves Yervoy

    Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.

  14. 2012Bristol-Myers Squibb

    FDA approves Eliquis

    The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.

  15. 2014Bristol-Myers Squibb

    FDA approves Opdivo

    The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.

  16. 2019Bristol-Myers Squibb

    Celgene acquisition closes

    BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.

  17. 2019Pfizer

    Albert Bourla becomes CEO

    Albert Bourla became CEO of Pfizer in 2019. A veterinarian by training who joined Pfizer Animal Health in 1993, Bourla became CEO on January 1, 2019 and Chairman in 2020.

  18. 2020Bristol-Myers Squibb

    MyoKardia deal and a GAAP loss

    BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.

  19. 2020Pfizer

    BioNTech COVID Vaccine Partnership

    Pfizer and BioNTech brought Comirnaty through emergency authorization.

  20. 2022Bristol-Myers Squibb

    Turning Point bought as Revlimid generics arrive

    BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.

  21. 2023Bristol-Myers Squibb

    Chris Boerner becomes CEO

    Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.

  22. 2023Pfizer

    Seagen Acquisition

    Pfizer completed the $43 billion Seagen acquisition.

  23. 2024Bristol-Myers Squibb

    Karuna, Mirati and RayzeBio close; Cobenfy approved

    The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.

  24. 2025Bristol-Myers Squibb

    BioNTech partnership, Orbital deal and $48.2B revenue

    BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.

  25. 2025Pfizer

    Chris Boshoff Becomes CSO

    Chris Boshoff became Chief Scientific Officer and President, Research & Development effective January 1, 2025.

  26. 2025Pfizer

    Metsera Acquisition

    Pfizer completed its acquisition of obesity drug developer Metsera in November 2025 for up to about $10 billion including CVRs.

  27. 2025Pfizer

    FY2025 Revenue Base

    Pfizer reported $62.579 billion of FY2025 revenue.

  28. 2026Bristol-Myers Squibb

    Guidance raised and merger reports denied

    On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.

  29. 2026Pfizer

    Innovent Oncology Collaboration

    Pfizer signed a 12-program cancer collaboration with Innovent Biologics: $650 million upfront and up to $9.85 billion in milestones.

Acquisitions

Bristol-Myers Squibb

  • Orbital Therapeutics2025$1.5B
  • Mirati Therapeutics2024$4.8B
  • RayzeBio2024$4.1B
  • Karuna Therapeutics2024$14B
  • Turning Point Therapeutics2022$4.1B
  • MyoKardia2020$13.1B
All Bristol-Myers Squibb acquisitions

Pfizer

  • Metsera, Inc.2025$7B
  • Seagen Inc.2023$43B
  • Medivation Inc.2016$14B
  • Wyeth2009$68B
  • Pharmacia Corporation2003$60B
  • Warner-Lambert Company2000$111B
All Pfizer acquisitions

Questions about Bristol-Myers Squibb vs Pfizer

Who is the CEO of Bristol-Myers Squibb Company and Pfizer Inc.?

Bristol-Myers Squibb Company is led by Christopher Boerner and Pfizer Inc. is led by Albert Bourla. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.

When was Bristol-Myers Squibb Company founded vs Pfizer Inc.?

Pfizer Inc. was founded in 1849 — 38 years before Bristol-Myers Squibb Company, which was founded in 1887. Pfizer Inc.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Bristol-Myers Squibb Company.

How many employees does Bristol-Myers Squibb Company have compared to Pfizer Inc.?

Bristol-Myers Squibb Company employs approximately 32,500 people, while Pfizer Inc. employs approximately 75,000. Pfizer Inc. has the larger workforce at 75,000 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).

Where are Bristol-Myers Squibb Company and Pfizer Inc. headquartered?

Both Bristol-Myers Squibb Company and Pfizer Inc. are headquartered in United States. Their local rules and tax obligations may still differ.

Who founded Bristol-Myers Squibb Company and Pfizer Inc.?

Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. Pfizer Inc. was founded by Charles Pfizer, Charles Erhart.

Which company has a longer operating history — Bristol-Myers Squibb Company or Pfizer Inc.?

Pfizer Inc. has been operating for approximately 177 years, making it the more established of the two companies. Bristol-Myers Squibb Company has been in operation for around 139 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Pfizer overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.